1,083
+4.23%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PeptiDream
Its shares trade on Tokyo Stock Exchange under the ticker 4587.T. It has been listed since 11 June 2013. In the fiscal year to 31 December 2025, it reported revenue of ¥18.52bn and a net loss of ¥3.75bn. At that date it held total assets of ¥77.03bn and shareholders' equity of ¥51.53bn.
PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. The company is headquartered in Kawasaki-Shi, Kanagawa-Ken. The company went IPO on 2013-06-11. The firm operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The firm is involved in the business centered on drug development based on special peptides. The firm's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 2013
- Employees
- 128
- Website
- peptidream.com ↗
Leadership
Pay as last reported
- Dr. Patrick ReidPresident, Chief Executive Officer, Representative Director, since 2008¥161.9m
- Dr. Kiyofumi KaneshiroChief Financial Officer, Vice President, Director, since 2018¥161.9m
- Dr. Christian CunninghamChief Scientific Officer
- Dr. Masato MurakamiChief Medical Officer, President of Subsidiary
- Mr. Yukinori HanafusaIndependent Director
- Mr. Kiichiro KamiyaIndependent Director
- Ms. Junko NishiyamaIndependent Director
- Ms. Junko UtsunomiyaIndependent Director
- Ms. Yuko OkimotoDirector of Investor Relations and Public Relations Unit, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 78
- Social
- 57
- Governance
- 60
- Direct emissions (scope 1)
- 3,156.06 t
- Energy emissions (scope 2)
- 9,716 t
- Value chain emissions (scope 3)
- 96,847 t
- Women in the workforce
- 39.3%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PeptiDream Inc has a strong reputation in the biopharmaceutical industry, recognized for its innovative peptide drug discovery technologies.
- The company has a robust and diverse pipeline of potential drug candidates, which positions it well for future growth.
- PeptiDream Inc benefits from strategic collaborations with major pharmaceutical companies, providing access to additional resources and expertise.
Weaknesses
- PeptiDream Inc may face challenges in scaling up its production processes to meet commercial demand for its peptide drugs.
- The company's heavy reliance on collaborations for revenue generation exposes it to potential risks if these partnerships fail to deliver expected results or terminate.
- PeptiDream Inc's limited global presence and market penetration may hinder its ability to compete effectively against larger, more established competitors.
Opportunities
- The increasing focus on personalized medicine and targeted therapies presents significant opportunities for PeptiDream Inc's peptide drug discovery technologies.
- Expansion into emerging markets, where access to advanced biopharmaceuticals is growing, could open up new avenues for revenue and market share growth.
- PeptiDream Inc has the potential to leverage its expertise in peptide drug discovery to explore applications in other therapeutic areas, diversifying its product offerings.
Threats
- PeptiDream Inc operates in a highly competitive industry, facing constant challenges from other biopharmaceutical companies in developing and commercializing innovative drugs.
- The regulatory environment governing drug development and approval can present obstacles and delays for PeptiDream Inc's pipeline candidates, impacting their time-to-market and potential profitability.
- Unexpected scientific or technological breakthroughs by competitors could render PeptiDream Inc's current peptide drug discovery technologies obsolete.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.